... One part of the drug recognizes and binds to cancer cells, while the other part attacks and kills the cancer cell.Bispecific antibodies approved to treat relapsed or refractory DLBCL include apcoritamab-bysp (Epkinly) and glofitamab-gxbm (Columvi).Other drugs approved for relapsed/refractory DLBCL in certain situations include Selinexor (Xpovio) and ...
... One part of the drug recognizes and binds to cancer cells, while the other part attacks and kills the cancer cell.Bispecific antibodies approved to treat relapsed or refractory DLBCL include apcoritamab-bysp (Epkinly) and glofitamab-gxbm (Columvi).Other drugs approved for relapsed/refractory DLBCL in certain situations include Selinexor (Xpovio) and ...
... Selinexor (Xpovio) is a nuclear export inhibitor that can be used to treat recurrent diffuse large B-cell lymphoma (DLBCL).4. ImmunotherapyImmunotherapy treatments support the immune system in targeting and destroying lymphoma cells or slowing their growth. ...
... Selinexor (Xpovio) is a nuclear export inhibitor that can be used to treat recurrent diffuse large B-cell lymphoma (DLBCL).4. ImmunotherapyImmunotherapy treatments support the immune system in targeting and destroying lymphoma cells or slowing their growth. ...